Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 1312, pseudogene (RNU6-1312P) is a genomic sequence in humans derived from the highly conserved U6 small nuclear RNA gene, a fundamental component of the spliceosomal machinery[1][3]. RNU6-1312P is a processed pseudogene, meaning it has lost its ability to produce a functional RNA or protein but persists in the genome as a non-coding fragment. The parental U6 snRNA orchestrates catalytic steps of intron removal in eukaryotic mRNA splicing[1][3]. Although some pseudogenes have regulatory functions in rare cases (such as microRNA sponge activities), RNU6-1312P is not documented to play any known functional, regulatory, or disease-related role, nor is it a molecular drug target[4]. It therefore represents a non-functional genetic remnant rather than a biologically or pharmacologically active molecule. If structured information is needed for biomedical targeting, this entry should be flagged as incorrect for use as a target.
Not applicable; there are no known drugs or mechanisms targeting RNU6-1312P.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1312, pseudogene (RNU6-1312P).